

Shampa Das

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3612085/publications.pdf>

Version: 2024-02-01

34
papers

1,005
citations

394421

19
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

1060
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2862-2869.	3.0	98
2	Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. <i>Annals of Oncology</i> , 2011, 22, 431-437.	1.2	87
3	Ceftazidime+Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. <i>Clinical and Translational Science</i> , 2019, 12, 151-163.	3.1	65
4	Avibactam Pharmacokinetic/Pharmacodynamic Targets. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	62
5	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 370-380.	2.6	59
6	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014). <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 418-429.	2.5	52
7	Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	51
8	Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. <i>Drug Metabolism and Disposition</i> , 2014, 42, 932-942.	3.3	44
9	Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6252-6259.	3.2	44
10	Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 211-218.	2.0	36
11	Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00172.	2.4	34
12	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	34
13	Ceftaroline fosamil doses and breakpoints for <i>Staphylococcus aureus</i> in complicated skin and soft tissue infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 425-431.	3.0	31
14	Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. <i>Drugs in R and D</i> , 2018, 18, 221-230.	2.2	30
15	Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime+avibactam in healthy Japanese volunteers. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 551-558.	1.7	28
16	Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 345-355.	2.0	27
17	Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime+avibactam or ceftaroline fosamil+avibactam. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 331-340.	2.0	25
18	A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. <i>Critical Care</i> , 2012, 16, R31.	5.8	24

#	ARTICLE	IF	CITATIONS
19	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
20	Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
21	Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor- $\hat{\pm}$ (TNF- $\hat{\pm}$) using AZD9773, an anti-TNF- $\hat{\pm}$ immune Fab, in murine CLP sepsis. Inflammation Research, 2014, 63, 149-160.	4.0	18
22	Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. Paediatric Drugs, 2021, 23, 465-484.	3.1	18
23	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum- $\hat{2}$ -Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	15
24	Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115292.	1.8	15
25	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0029321.	3.2	12
26	Pharmacodynamics of the Novel Metallo- $\hat{2}$ -Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
27	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	10
28	Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology, 2020, 76, 349-361.	1.9	9
29	Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 1334-1343.	3.0	8
30	Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. Clinical Pharmacology in Drug Development, 2019, 8, 682-694.	1.6	6
31	Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF- $\hat{\pm}$ polyclonal fragment antibody AZD9773 in patients with severe sepsis. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 591-599.	1.8	5
32	Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. International Journal of Antimicrobial Agents, 2019, 53, 830-837.	2.5	5
33	Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218121.	3.2	1
34	Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	0